Marko Pregel

Marko Pregel is an accomplished professional in the field of gene therapy, currently serving as the Executive Director and Program Leader at Solid Biosciences since June 2025, where responsibilities include leading adeno-associated virus gene therapy programs and defining project strategies. Previously, Marko held the position of Early Global Program Team Leader at Alexion Pharmaceuticals, guiding the strategy for a cardiac AAV gene therapy. Marko's extensive experience at Pfizer includes roles as Director and Research Project Leader, overseeing multiple AAV gene therapy projects and collaborations, as well as serving as an Associate Research Fellow and Senior Principal Scientist. Marko began a career in research at Genzyme as a Principal Scientist and has a foundational background in enzymology from postdoctoral positions at the National Research Council and Collège de France. Marko holds a Ph.D. in Physical Organic Chemistry from Queen's University.